This weekly news brief provides a quick view at all of the news from the week of February 9-13, 2026.
This week's brief covers the first FDA-approved AI-backed medical device for lung cancer screening and a risk model for predicting cardiac events in patients with cancer and acute coronary syndrome.
Read Dr. Hudis' interview about the new ASCO AI in Oncology platform at "Introducing ASCO AI in Oncology: A Conversation With Clifford A. Hudis, MD, FACP, FASCO"
To learn more about FDA clearance for eyonic LCS, read "First AI-Backed Medical Device FDA Approved for Detection and Diagnosis in Lung Cancer Screening"
For more information about the ONCO-ACS predictive model, read "Risk Model Enhances Prediction of Subsequent Cardiac Events in Patients With Cancer," or see the source report in The Lancet.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.